Dr. Lonial on Treating Early Relapse in Multiple Myeloma

Video

In Partnership With:

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the management of patients with relapsed multiple myeloma.

Patients with early relapse will progress on one prior line of therapy, says Lonial. However, patient outcomes in this space have improved dramatically over the past 10 years.

Notably, some patients with early relapse may experience a remission duration that is as long as their original remission, explains Lonial. This is due, in part, to the availability of agents such as daratumumab (Darzalex), carfilzomib (Kyprolis), and pomalidomide (Pomalyst).

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD